两种化疗方法治疗32例晚期胃癌患者的临床观察

Two chemotherapy in treating 32 patients with advanced gastric cancer

目的观察比较晚期胃癌患者采用S一1联合紫杉醇与5一氟尿嘧啶（5-Fu）联合紫杉醇两种方案治疗的近期疗效、不良反应及临床受益反应率。方法将所选32例晚期胃癌患者，随机分为两组（试验组和对照组各16例），试验组1—14d内给予S-1，80mS／m2，分2次口服（餐后服用），同时在第1、8、15天紫杉醇60mg／m2（静脉注射3h）。S-1用药14d停药，14d为1个周期，紫杉醇4周为1个周期。对照组l-5d内给予5-Fu500mg／m2和亚叶酸钙（cF）20mg／m2静脉滴注，每4周为1个周期，紫杉醇同试验组。两组分别治疗2个周期后进行疗效评价，比较两组近期疗效、不良反应及临床受益反应。结果两组患者均可进行评价。评价结果中试验组和对照组的临床受益反应率分别为75．0％和43．8％，两组比较差异有统计学意义（P〈0．05）。非血液系统毒性中的恶心呕吐发生率分别为25．0％和62．5％，两组比较差异有统计学意义（19〈0．05）。结论采用s一1联合紫杉醇治疗晚期胃癌的临床受益率显著增加，不良反应较轻。

Objective To observe and compare the short- term efficacy, side effects and clinical benefit response rates of two chemotherapy for 32 patients with gastric cancer treated with S - 1 combined with paclitaxel and 5 -Fu plus paclitaxel. Methods The selected 32 patients with advanced gastric cancer were randomly divided into two groups （ experimental group and control group, 16 cases for each group）. To the fourteenth day from the first day, the experimental group was given a set of S - 1, 80 mg/m2, 2 times orally （ after meal）, at the same time given paclitaxel, 60 mg/m2 in the first day, the eighth day and the fifteenth day. S - 1 treatment for 14 days, for a period 14 of days. Paclitaxel was for a period of 4 weeks. From the first day to the fifth day, the control group was given 5 - Fu 500 mg/m2 and CF 20 mg/m2 intravenously every 4 weeks of a cycle. The paclitaxel was given in the same time as the experimental group. After two cycles of treatment, efficacy, curative effect, side effects, and clinical benefit response were compared. Results Two groups of patients can be evaluated. In evaluation of the results of the experimental group and control group, clinical benefit response rates were 75.0% and 43.8% （ P 〈 0.05 ）, there was satistically significant difference between the two groups. The incidence of nausea ad vomiting were 25.0% and 62.5%, there was satistically significant difference between the two groups. Conclusions S - 1 plus paclitaxel in the treatment of advanced gastric cancer, clinical benefit rate is significantly increased and toxicity is mild.